We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 0.16% | 123.00 | 122.20 | 122.80 | 124.00 | 122.20 | 122.60 | 632,316 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Trust,ex Ed,religious,charty | -39.79M | -56.02M | -0.0840 | -14.55 | 814.75M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/6/2018 07:01 | Autolus to ipo on Nasdaq 22/6 | ltinvestor | |
10/6/2018 11:59 | Autolus has a unique advantage over other car T therapies in that their car T has a built in “off switch”.This will help reduce adverse reactions found with other T cell therapies.Autolus excites me more than their other subsidiary holdings and in time has the potential to be worth billions... | ltinvestor | |
08/6/2018 11:25 | Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus̶ The registration statement discloses an indicative pricing range for the proposed offering of U.S.$15.00 – U.S.$17.00 per ADS. This would represent an increase in value of Syncona’s current shareholding in Autolus (compared to the 30 April 2018 sterling holding value) of £49.5 – £67.7 million[1] (7.4p-10.2p per Syncona share). The proposed maximum aggregate offering amount specified in the filing is U.S.$125.0 million, which assumes that the offering price is at the midpoint of the indicative pricing range and does not include the underwriters’ option to purchase additional ADSs. | alan@bj | |
31/5/2018 16:47 | Indeed it is moving along nicely. I like the business models which allows exposure to a portfolio of life science start-ups which would otherwise be unavailable for investment. Definitely less risky than buying in to early stage companies reliant on a single technology. | audigger | |
25/5/2018 14:54 | .....and today another high.Where is everybody? | ltinvestor | |
24/5/2018 08:22 | Today the share price has reached an all time high and no wonder with its holdings.Under the radar at the moment with Pi’s but not institutions. | ltinvestor | |
15/5/2018 13:20 | hxxps://www.business Apparently a poster on the results of the LOCATE clinical trial (NCT02680041) will be presented in the next week. 220 patients for: Primary Outcome Measures : The fraction of patients for whom 18F-fluciclovine PET/CT alters patient planned treatment through detection of disease. [ Time Frame: 2-22 days post PET CT ] The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT Secondary Outcome Measures : The fraction of patients for whom 18F-fluciclovine PET/CT alters patient actual treatment [ Time Frame: 6 months ] The rate of detection of any disease site by 18F-fluciclovine PET/CT in the study population [ Time Frame: 1 week ] The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT The rate of detection of 1) local and pelvic disease and 2) distant metastases with 18F-fluciclovine PET/CT in the study population [ Time Frame: 1 week ] The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally | luxaeterna1 | |
15/5/2018 10:56 | I was very fortunate and bought in during the first few weeks of the fund @ about £1.30. Thankfully it was a modest purchase, offsetting some fairly terrible other stocks in my portfolio! | luxaeterna1 | |
13/5/2018 09:48 | I bought a large number at £1.65 so very happy. | ltinvestor | |
13/5/2018 08:42 | I am invested here. I bought in at 159p. | alan@bj | |
13/5/2018 07:14 | Alan.Autolus have built a “switch” in the Car T cell so they have the ability to can turn off the treatment at any time.Syncona is under the PI radar at the moment but not the institutions.This is one investment that you lock in the bottom drawer and watch it grow year on year.Dyor and do not take this as investment advice... | ltinvestor | |
12/5/2018 13:37 | Thank you Iti. | alan@bj | |
12/5/2018 12:19 | It is on one of the forms and apparently is an approximation.If you google Autolus you will find a couple of articles re the listing etc | ltinvestor | |
11/5/2018 16:24 | Where did you find that information, Iti? Is Syncona participating in the fund raising? | alan@bj | |
11/5/2018 15:42 | Raising $100m prior to listing.. | ltinvestor | |
10/5/2018 19:26 | Therein lies opportunity :-) DL | davidlloyd | |
08/5/2018 07:20 | No price movement on announcement as no details. | brexitplus | |
08/5/2018 06:42 | Syncona have a 38.6% share of Autolus and the Nasdaq listing should show a significant uplift in Synconas nav. | ltinvestor | |
08/5/2018 06:12 | Autolus files for proposed initial public offering in the United States 8 May 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus̶ | brexitplus | |
02/5/2018 18:11 | The highly encouraging rns in full: | rambutan2 | |
02/5/2018 08:35 | Axumin sales price is ~ $3000 per dose, at the RNS announced of 5000 doses per quarter that should result in approximate ~ $60m annual sales revenue, already indicated as profitable. Now - with sales rising at roughly 35% per quarter there is serious room for expansion! At current growth trend Blue Earth could be a $200m revenue co in 12 months time? | luxaeterna1 | |
02/5/2018 07:20 | Yes, the portfolio companies are progressing very well.Autolus possible Ipo in the US? | ltinvestor | |
02/5/2018 07:18 | Excellent news from Blue Earth. | alan@bj | |
10/4/2018 07:39 | Novartis acquiring Avexis for $8.7bn!Syncona own 74% Of Freeline Which is in the same field.... | ltinvestor | |
28/3/2018 15:17 | Not sure why the fall, you'd have to assume some stock hit the market somewhere. I had not realised the scope for further Fluciclovine PET imaging, they currently have a EU/US license for prostate scanning, with further clinical trials ongoing with female breast cancer ( hxxps://clinicaltria There was an unusual medical science case documented in January 2018, a 77year old prostate cancer patient was diagnosed with a secondary breast cancer tumour that was discovered by the fluciclovine Quite interesting considering it has not been validated for that condition (in practice many tumours could be be flagged in a similar way). | luxaeterna1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions